Privately held biotech TransTech Pharma Inc. stands to gain more than $1.1 billion in a new partnership with Forest Laboratories Inc. to develop and commercialize a new class of glucose-lowering agents, known as functionally liver-selective glucokinase activators (GKAs), to treat diabetes. (BioWorld Today) Read More
